Thomas D Schmittgen, Ph.D.
Chair Of Pharmaceutics And The V. Ravi Chandran Professor Of Pharmaceutical Sciences
About Thomas D Schmittgen
Thomas D. Schmittgen, Ph.D. is a professor and Chair in the Department of Pharmaceutics at the University of Florida in Gainesville and is the V. Ravi Chandran Professor of Pharmaceutical Sciences. Dr. Schmittgen holds both undergraduate (Pharmacy) and graduate degrees (Pharmaceutics) from the Ohio State University. He was a National Research Service Award (NIH) postdoctoral fellow at the University of Southern California from 1992-1995. He served on the faculty at Washington State University College of Pharmacy from 1995-2002. Dr. Schmittgen returned to the Ohio State University in 2002 where he remained on the faculty for 13 years, serving as chair of the Division of Pharmaceutics from 2000-2015. Dr. Schmittgen was hired at the University of Florida in 2015 through the UF Preeminence Initiative.
Accomplishments
Best basic science paper
2017
·
University of Florida
Fellow
2016
·
American Association of Pharmaceutical Scientists
Co-author of the 21st most cited scientific paper of all time
2014
·
Reported in Nature, Oct. 2014
Inventor of the year
2011
·
TechColumbus Innovation Awards
Individual National Research Service Award
1993-1995
·
National Institutes of Health
Fellow
1990-1991
·
Berlex
Teaching Profile
Courses Taught
2016-2022,2024
PHA7979 Advanced Research
2016-2018,2020-2024
PHA7980 Research for Doctoral Dissertation
2019-2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2018-2020,2023-2024
PHA6910 Supervised Research
2020-2021
PHA6971 Research for Master’s Thesis
2019-2020
PHA6183 Pharmaceutical Gene Delivery
2018,2020-2023,2023-2024
PHA6170C Pharmaceutical Product Formulation
2017-2024
GMS6065 Fundamentals of Cancer Biology
2019,2023-2024
PHA6935 Selected Topics in Pharmacy
2018
PHA5176 Drug Delivery Systems
2018
MCB4911 Supervised Research in Microbiology and Cell Science
2018
GMS7980 Research for Doctoral Dissertation
2017-2018
GMS5905 Special Topics in Biomedical Sciences
2021
PHA6894 Introduction to Graduate Studies
2021-2024
PHA6418 Model-Informed Drug Development
2021
PHA5930 Sem Pharm Research
2022-2024
PHA6416 Pharmaceutical Analysis I
2022-2024
PHA6740 Fundamentals of Grant Writing in the Pharmaceutical Sciences
Research Profile
Dr. Schmittgen’s research focuses on noncoding RNAs and cancer with emphasis on the use of microRNAs as therapeutic or diagnostic agents. A paper he co-authored in 2001 describing the relative method of gene quantification has been cited over 105,000 times and was ranked in 2014 by the international journal Nature as the 21st most cited scientific article of all time. Dr. Schmittgen has been continuously funded by federal agencies (NIH, DOD) for the past 20 years. His lab was the first to establish a link between altered microRNA expression in pancreatic cancer. Dr. Schmittgen’s lab is currently developing exosomes/microvesicles as targeted drug delivery systems for the treatment of cancer. Dr. Schmittgen is a member of the American Association for Cancer Research, American Association for the Advancement of Science and is a Fellow of the American Association of Pharmaceutical Scientists.
Areas of Interest
- Cancer
- Drug delivery
- Drug development
- Exosomes
- Extracellular vesicles
- MircroRNA
- RNA
- Therapeutics
Open Researcher and Contributor ID (ORCID)
0000-0002-2812-8546
Publications
2024
Epigenetic small-molecule screen for inhibition and reversal of acinar ductal metaplasia in mouse pancreatic organoids.
Frontiers in pharmacology.
15
[DOI] 10.3389/fphar.2024.1335246.
[PMID] 38510657.
2024
Peptide-based capture-and-release purification of extracellular vesicles and statistical algorithm enabled quality assessment.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.02.06.578050.
[PMID] 38370748.
2024
Rerouting cardiovascular management following gastric bypass surgery: Dose optimization of carvedilol using population-based analysis.
British journal of clinical pharmacology.
90(9):2223-2235
[DOI] 10.1111/bcp.16129.
[PMID] 38852609.
2024
Small molecular weight epigenetic inhibitors modulate the extracellular matrix during pancreatic acinar ductal metaplasia.
Biochemical and biophysical research communications.
736
[DOI] 10.1016/j.bbrc.2024.150496.
[PMID] 39128264.
2023
Disclosing quantitative RT-PCR raw data during manuscript submission: a call for action.
Molecular oncology.
17(5):713-717
[DOI] 10.1002/1878-0261.13418.
[PMID] 36916500.
2023
Epigenetic Small-Molecule Screen for Inhibition and Reversal of Acinar Ductal Metaplasia in Mouse Pancreatic Organoids.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.11.27.567685.
[PMID] 38077007.
2023
Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure, Innovations, and Initial Outcomes.
Cancer control : journal of the Moffitt Cancer Center.
30
[DOI] 10.1177/10732748231197878.
[PMID] 37703814.
2023
Transcriptional Profile of Human Pancreatic Acinar Ductal Metaplasia
Gastro Hep Advances.
2(4):532-543
[DOI] 10.1016/j.gastha.2023.02.003.
[PMID] 37425649.
2022
Acinar Cell-Enriched-MicroRNA-802 Connects the Dots Between Kras Signaling, Acinar Ductal Metaplasia, and Pancreatic Cancer.
Gastroenterology.
162(1):48-50
[DOI] 10.1053/j.gastro.2021.10.011.
[PMID] 34662582.
2022
Method for Isolating Extracellular Vesicles from Human Neural Stem Cells Expanded Under Neurosphere Culture.
Methods in molecular biology (Clifton, N.J.).
2389:87-94
[DOI] 10.1007/978-1-0716-1783-0_8.
[PMID] 34558004.
2022
Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia
Cell Death Discovery.
8(1)
[DOI] 10.1038/s41420-022-01165-4.
[PMID] 36055991.
2021
Enrichment of the erythrocyte miR-451a in brain extracellular vesicles following impairment of the blood-brain barrier.
Neuroscience letters.
751
[DOI] 10.1016/j.neulet.2021.135829.
[PMID] 33727125.
2021
Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer.
Cancer metastasis reviews.
40(3):761-776
[DOI] 10.1007/s10555-021-09995-x.
[PMID] 34591242.
2020
Alterations in mouse spinal cord and sciatic nerve microRNAs after the chronic constriction injury (CCI) model of neuropathic pain.
Neuroscience letters.
731
[DOI] 10.1016/j.neulet.2020.135029.
[PMID] 32380144.
2020
Enhancing African American Participation in Biospecimens: A Case in Point for Pancreatic Cancer.
Cancer health disparities.
29(12)
[DOI] 10.1158/1538-7755.DISP20-PO-236.
[PMID] 34296063.
2020
Human Colon Mucosal Biofilms and Murine Host Communicate via Altered mRNA and microRNA Expression during Cancer.
mSystems.
5(1)
[DOI] 10.1128/mSystems.00451-19.
[PMID] 31937674.
2020
Loss of RE-1 silencing transcription factor accelerates exocrine damage from pancreatic injury.
Cell death & disease.
11(2)
[DOI] 10.1038/s41419-020-2269-7.
[PMID] 32080178.
2020
Method for improved integrity of RNA isolated from Matrigel cultures.
MethodsX.
7
[DOI] 10.1016/j.mex.2020.100966.
[PMID] 32637337.
2019
Exosomal miRNA Cargo as Mediator of Immune Escape Mechanisms in Neuroblastoma.
Cancer research.
79(7):1293-1294
[DOI] 10.1158/0008-5472.CAN-19-0021.
[PMID] 30936073.
2019
Knockout of Acinar Enriched microRNAs in Mice Promote Duct Formation But Not Pancreatic Cancer.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-47566-x.
[PMID] 31367007.
2018
CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.
Oncotarget.
9(40):26032-26045
[DOI] 10.18632/oncotarget.25430.
[PMID] 29899840.
2018
MicroRNAs Targeting Caspase-3 and -7 in PANC-1 Cells.
International journal of molecular sciences.
19(4)
[DOI] 10.3390/ijms19041206.
[PMID] 29659498.
2018
Pancreatic Cancer Related Health Disparities: A Commentary.
Cancers.
10(7)
[DOI] 10.3390/cancers10070235.
[PMID] 30021952.
2017
Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading.
Pharmaceutical research.
34(5):1053-1066
[DOI] 10.1007/s11095-017-2123-5.
[PMID] 28315083.
2017
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells.
Journal of extracellular vesicles.
6(1)
[DOI] 10.1080/20013078.2017.1324730.
[PMID] 28717420.
2017
Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma.
Non-coding RNA.
3(3)
[DOI] 10.3390/ncrna3030024.
[PMID] 29657295.
2017
Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery
Journal of Extracellular Vesicles.
6(1)
[DOI] 10.1080/20013078.2017.1333882.
[PMID] 28717424.
2017
miR-216 and miR-217 expression is reduced in transgenic mouse models of pancreatic adenocarcinoma, knockout of miR-216/miR-217 host gene is embryonic lethal.
Functional & integrative genomics.
17(2-3):203-212
[DOI] 10.1007/s10142-016-0512-1.
[PMID] 27541609.
2017
miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway.
Biochemical and biophysical research communications.
487(3):709-715
[DOI] 10.1016/j.bbrc.2017.04.121.
[PMID] 28442344.
2017
MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2.
Cell death & disease.
8(3)
[DOI] 10.1038/cddis.2017.123.
[PMID] 28358369.
2017
The pancreatic tumor microenvironment drives changes in miRNA expression that promote cytokine production and inhibit migration by the tumor associated stroma.
Oncotarget.
8(33):54054-54067
[DOI] 10.18632/oncotarget.10722.
[PMID] 28903323.
2016
Anti-Invasion and Anti-Migration Effects of Mir-199A-3P in Hepatocellular Carcinoma Are Due in Part to Targeting Cd151
International Journal of Oncology.
49(5):2037-2045
[DOI] 10.3892/ijo.2016.3677.
2016
Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA.
Scientific reports.
6
[DOI] 10.1038/srep22137.
[PMID] 26916931.
2016
Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma.
Oncotarget.
7(33):53165-53177
[DOI] 10.18632/oncotarget.10242.
[PMID] 27363020.
2015
Dietary apigenin reduces LPS-induced expression of miR-155 restoring immune balance during inflammation.
Molecular nutrition & food research.
59(4):763-72
[DOI] 10.1002/mnfr.201400705.
[PMID] 25641956.
2014
A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.
Annals of surgical oncology.
21(1):133-8
[DOI] 10.1245/s10434-013-3240-y.
[PMID] 24046106.
2014
RNA isolation from mouse pancreas: a ribonuclease-rich tissue.
Journal of visualized experiments : JoVE.
(90)
[DOI] 10.3791/51779.
[PMID] 25145327.
2014
Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.
Antimicrobial agents and chemotherapy.
58(8):4682-9
[DOI] 10.1128/AAC.02405-14.
[PMID] 24890590.
2013
Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma.
HPB : the official journal of the International Hepato Pancreato Biliary Association.
15(4):260-4
[DOI] 10.1111/j.1477-2574.2012.00523.x.
[PMID] 23458262.
2013
HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts.
Cell death and differentiation.
20(12):1675-87
[DOI] 10.1038/cdd.2013.119.
[PMID] 24037088.
2013
Microbiomarkers with big impact in CLL.
Blood.
122(11):1843-4
[DOI] 10.1182/blood-2013-08-514117.
[PMID] 24030253.
2013
Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076402.
[PMID] 24098490.
2011
MicroRNA replacement therapy for cancer.
Pharmaceutical research.
28(12):3030-42
[DOI] 10.1007/s11095-011-0548-9.
[PMID] 21879389.
2011
miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor.
Biochemical and biophysical research communications.
406(4):518-23
[DOI] 10.1016/j.bbrc.2011.02.065.
[PMID] 21329664.
2011
miR-221 silencing blocks hepatocellular carcinoma and promotes survival.
Cancer research.
71(24):7608-16
[DOI] 10.1158/0008-5472.CAN-11-1144.
[PMID] 22009537.
2011
The role of microRNAs in human liver cancers.
Seminars in oncology.
38(6):752-63
[DOI] 10.1053/j.seminoncol.2011.08.001.
[PMID] 22082761.
2010
MicroRNAs are mediators of androgen action in prostate and muscle.
PloS one.
5(10)
[DOI] 10.1371/journal.pone.0013637.
[PMID] 21048966.
2010
miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.
Biochemical and biophysical research communications.
403(1):120-5
[DOI] 10.1016/j.bbrc.2010.10.130.
[PMID] 21055388.
2010
miR-31: a master regulator of metastasis?
Future oncology (London, England).
6(1):17-20
[DOI] 10.2217/fon.09.150.
[PMID] 20021205.
2010
Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection.
Diagnostic molecular pathology : the American journal of surgical pathology, part B.
19(3):135-43
[DOI] 10.1097/PDM.0b013e3181c4daaa.
[PMID] 20736742.
2009
A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets.
Nature protocols.
4(1):107-15
[DOI] 10.1038/nprot.2008.215.
[PMID] 19131963.
2009
Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.
Pancreas.
38(7):e190-9
[DOI] 10.1097/MPA.0b013e3181ba82e1.
[PMID] 19730150.
2009
In situ detection of mature microRNAs by labeled extension on ultramer templates.
BioTechniques.
46(2):115-26
[DOI] 10.2144/000113068.
[PMID] 19317656.
2009
Integrating the MicroRNome into the study of lung disease.
American journal of respiratory and critical care medicine.
179(1):4-10
[DOI] 10.1164/rccm.200807-1042PP.
[PMID] 18787215.
2009
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
Cancer research.
69(19):7569-76
[DOI] 10.1158/0008-5472.CAN-09-0529.
[PMID] 19773441.
2009
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice.
Hepatology (Baltimore, Md.).
50(4):1152-61
[DOI] 10.1002/hep.23100.
[PMID] 19711427.
2008
Analyzing real-time PCR data by the comparative C(T) method.
Nature protocols.
3(6):1101-8
[PMID] 18546601.
2008
Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.
Clinical cancer research : an official journal of the American Association for Cancer Research.
14(2):419-27
[DOI] 10.1158/1078-0432.CCR-07-0523.
[PMID] 18223217.
2008
Benign metastasizing leiomyoma of the lung: clinicopathologic, immunohistochemical, and micro-RNA analyses.
Diagnostic molecular pathology : the American journal of surgical pathology, part B.
17(3):145-50
[DOI] 10.1097/PDM.0b013e31815aca19.
[PMID] 18382364.
2008
Detection of microRNA expression in human peripheral blood microvesicles.
PloS one.
3(11)
[DOI] 10.1371/journal.pone.0003694.
[PMID] 19002258.
2008
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.
Cancer research.
68(9):3142-51
[DOI] 10.1158/0008-5472.CAN-08-0483.
[PMID] 18451139.
2008
High-throughput real-time PCR.
Methods in molecular biology (Clifton, N.J.).
429:89-98
[DOI] 10.1007/978-1-60327-040-3_7.
[PMID] 18695961.
2008
Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts.
Biochemical and biophysical research communications.
370(3):473-7
[DOI] 10.1016/j.bbrc.2008.03.120.
[PMID] 18387358.
2008
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis.
Cancer research.
68(13):5049-58
[DOI] 10.1158/0008-5472.CAN-07-6655.
[PMID] 18593903.
2008
MicroRNAs and cancer: profile, profile, profile.
International journal of cancer.
122(5):969-77
[PMID] 18098138.
2008
MicroRNAs modulate the chemosensitivity of tumor cells.
Molecular cancer therapeutics.
7(1):1-9
[DOI] 10.1158/1535-7163.MCT-07-0573.
[PMID] 18187804.
2008
Part B–microRNAs: microRNA methods.
Methods (San Diego, Calif.).
44(1):1-2
[PMID] 18158126.
2008
Real-time PCR quantification of precursor and mature microRNA.
Methods (San Diego, Calif.).
44(1):31-8
[PMID] 18158130.
2008
Regulation of microRNA processing in development, differentiation and cancer.
Journal of cellular and molecular medicine.
12(5B):1811-9
[DOI] 10.1111/j.1582-4934.2008.00483.x.
[PMID] 18752632.
2008
Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors.
RNA (New York, N.Y.).
14(1):35-42
[PMID] 18025253.
2007
Computational analysis of biological functions and pathways collectively targeted by co-expressed microRNAs in cancer.
BMC bioinformatics.
8 Suppl 7(Suppl 7)
[PMID] 18047715.
2007
Dynamin 2 regulates riboflavin endocytosis in human placental trophoblasts.
Molecular pharmacology.
72(3):553-62
[PMID] 17565002.
2007
Expression profiling identifies microRNA signature in pancreatic cancer.
International journal of cancer.
120(5):1046-54
[PMID] 17149698.
2007
The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding.
The Journal of biological chemistry.
282(33):24262-9
[PMID] 17588946.
2007
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas.
Cancer cell.
12(3):215-29
[PMID] 17785203.
2006
Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines.
International journal of oncology.
29(3):655-63
[PMID] 16865282.
2006
Comparison of RNA assay methods used to normalize cDNA for quantitative real-time PCR.
Analytical biochemistry.
357(2):299-301
[PMID] 16930526.
2006
Increased expression of microRNA-155 in Epstein-Barr virus transformed lymphoblastoid cell lines.
Genes, chromosomes & cancer.
45(1):103-6
[PMID] 16175574.
2006
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology.
130(7):2113-29
[PMID] 16762633.
2006
MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts.
The Journal of biological chemistry.
281(27):18277-84
[PMID] 16675453.
2005
Diverse gene expression pattern during 5-fluorouridine-induced apoptosis.
International journal of oncology.
27(2):297-306
[PMID] 16010409.
2005
Real-time expression profiling of microRNA precursors in human cancer cell lines.
Nucleic acids research.
33(17):5394-403
[PMID] 16192569.
2004
A high-throughput method to monitor the expression of microRNA precursors.
Nucleic acids research.
32(4)
[PMID] 14985473.
2003
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
International journal of cancer.
107(2):323-9
[PMID] 12949815.
2003
Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
The Prostate.
55(4):308-16
[PMID] 12712410.
2003
Inhibition of pre-mRNA splicing by cisplatin and platinum analogs.
International journal of oncology.
23(3):785-9
[PMID] 12888918.
2001
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods (San Diego, Calif.).
25(4):402-8
[PMID] 11846609.
2001
Real-time quantitative PCR.
Methods (San Diego, Calif.).
25(4):383-5
[PMID] 11846607.
2000
Characterization of nitric oxide production following isolation of rat hepatocytes.
Toxicological sciences : an official journal of the Society of Toxicology.
53(1):56-62
[PMID] 10653521.
2000
Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR.
Journal of biochemical and biophysical methods.
46(1-2):69-81
[PMID] 11086195.
2000
Glutathione-dependent regulation of nitric oxide production in isolated rat hepatocyte suspensions.
Antioxidants & redox signaling.
2(4):767-77
[PMID] 11213481.
2000
Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods.
Analytical biochemistry.
285(2):194-204
[PMID] 11017702.
1996
Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Pharmaceutical research.
13(12):1887-91
[PMID] 8987090.
1994
Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology.
The Journal of urology.
152(5 Pt 1):1632-6
[PMID] 7933219.
1994
Effect of 5-fluoro- and 5-bromouracil substitution on the translation of human thymidylate synthase mRNA.
The Journal of biological chemistry.
269(23):16269-75
[PMID] 8206932.
1992
Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants.
Cancer chemotherapy and pharmacology.
30(1):25-30
[PMID] 1586977.
1991
Cultured human bladder tumors for pharmacodynamic studies.
The Journal of urology.
145(1):203-7
[PMID] 1898521.
1991
Pharmacodynamics of mitomycin C in cultured human bladder tumors.
Cancer research.
51(15):3849-56
[PMID] 1906778.
1984
Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart.
Life sciences.
35(3):285-91
[PMID] 6146909.
Grants
Sep 2023
ACTIVE
2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center
Role: Other
Funding: NATL INST OF HLTH NCI
Mar 2023
ACTIVE
R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Apr 2022
– Sep 2023
Gene expression in bone marrow exosomes during differentiation, phase II
Role: Principal Investigator
Funding: ERIVAN BIO
Feb 2022
– Jan 2023
Gene expression in bone marrow exosomes during differentiation, phase I
Role: Principal Investigator
Funding: ERIVAN BIO
Jun 2021
– Nov 2023
Modulation of microbiome function by host-derived noncoding small RNA
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Apr 2021
– Mar 2023
Takeda Research Agreement – Rogge Contract
Role: Co-Project Director/Principal Investigator
Funding: TAKEDA PHARM NORTH AMERICA
Jul 2020
– Dec 2023
OR-DRPD-ROF2020: Evaluating exosome heterogeneity by single vesicle sequencing
Role: Principal Investigator
Funding: UF RESEARCH
Sep 2019
ACTIVE
Novel Targeted Anticancer Agents from Marine Cyanobacteria
Role: Other
Funding: NATL INST OF HLTH NCI
May 2019
– Jul 2019
Organize 12th Symposium on New Development in Clinical Pharmacy and Clinical Pharmacology
Role: Principal Investigator
Funding: BOEHRINGER INGELHEIM PHARM INC
Sep 2018
– Aug 2023
2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center
Role: Other
Funding: NATL INST OF HLTH NCI
Dec 2017
– Dec 2018
Pfizer Agreement for Graduate Student Support
Role: Principal Investigator
Funding: PFIZER INC
Aug 2017
– Dec 2019
The Novel Role of REST in the Development of Pancreatic Ductal Adenocarcinoma
Role: Other
Funding: NATL INST OF HLTH NCI
Aug 2015
– Jul 2019
Targeted delivery of microRNA-loaded microvesicle for cancer therapy
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Dec 2004
– Jun 2021
Pfizer Graduate Fellowship Award/Donation for PK/PD Study – Dr. Derendorf
Role: Principal Investigator
Funding: PFIZER INC
Education
Post Doc – Biochemistry & Molecular Biology
1995
·
University of Southern California
Ph.D. – Pharmaceutics
1992
·
Ohio State University
B.S. – Pharmacy
1985
·
Ohio State University
Contact Details
Phones:
- Business:
- (352) 273-8028
Emails:
- Business:
- tschmittgen@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100494
GAINESVILLE FL 32610 - Business Street:
-
2033 MOWRY RD.
CGRC 459
GAINESVILLE FL 32608